Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYMAKER-U06 Substudy 06B in Advanced Esophageal Cancer
NCT05319730Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- May 2023
- Primary completion
- Jun 2027
- Countries
- 14
01
Overview
Phase 2, randomised, open-label trial of sacituzumab tirumotecan and mk-4830 in Esophageal Squamous Cell Carcinoma (ESCC) (5 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants Experiencing Dose-Limiting Toxicities at 3 weeks, Number of Participants Who Experienced an Adverse Event at 3 weeks and 2 more. Started May 2023; status: recruiting.
02
Drugs
sacituzumab tirumotecanmk-4830
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05319730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05319730.